A phase II gene therapy study in patients with non-small cell lung cancer using SCH58500 (rAd/p53) in combination with chemotherapy for multiple cycles

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A phase II gene therapy study in patients with non-small cell lung cancer using SCH58500 (rAd/p53) in combination with chemotherapy for multiple cycles
Date receipt dossier: 
18 aoû 1997
Pharmaceutical study code: 
I97-076-03
Company / Sponsor: 
Schering Plough NV/SA
Phase: 
II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Non-Small Cell Lung Cancer
Therapeutic approach: 
Tumor suppressor gene
Genetic modification: 
Wild-type p53
Method of transfer of nucleic acid of interest: 
Human Adenovirus serotype 5
Administered biological material: 
Recombinant Adenovirus D (E3, E1A, E1B, pIX)
Route of administration: 
Intratumoral
Locations in Belgium: 
Akademisch Ziekenhuis, Vrije Universiteit Brussel
Type of procedure: 
Contained use only
Current status: 
Authorized